
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><?origin nihpa?><?iso-abbr Nat. Med.?><?submitter-system nihms?><?submitter-canonical-name Nature Publishing Group?><?submitter-canonical-id NATURE-STRUCTUR?><?submitter-userid 1045?><?submitter-authority publisher?><?submitter-login nature-structure?><?submitter-name Nature Publishing Group (obsolete)?><?domain nihpa?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">9502015</journal-id><journal-id journal-id-type="pubmed-jr-id">8791</journal-id><journal-id journal-id-type="nlm-ta">Nat Med</journal-id><journal-id journal-id-type="iso-abbrev">Nat. Med.</journal-id><journal-title-group><journal-title>Nature medicine</journal-title></journal-title-group><issn pub-type="ppub">1078-8956</issn><issn pub-type="epub">1546-170X</issn></journal-meta><article-meta><article-id pub-id-type="pmcid">2974790</article-id><article-id pub-id-type="pmid">20972433</article-id><article-id pub-id-type="doi">10.1038/nm.2246</article-id><article-id pub-id-type="manuscript">nihpa238550</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>The TLX1 oncogene drives aneuploidy in T-cell transformation </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>De Keersmaecker</surname><given-names>Kim</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Real</surname><given-names>Pedro Jose</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref rid="FN2" ref-type="author-notes">*</xref><xref rid="FN3" ref-type="author-notes">†</xref></contrib><contrib contrib-type="author"><name><surname>Gatta</surname><given-names>Giusy Della</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Palomero</surname><given-names>Teresa</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Sulis</surname><given-names>Maria Luisa</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tosello</surname><given-names>Valeria</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Van Vlierberghe</surname><given-names>Pieter</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barnes</surname><given-names>Kelly</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Castillo</surname><given-names>Mireia</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Sole</surname><given-names>Xavier</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Hadler</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lenz</surname><given-names>Jack</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Aplan</surname><given-names>Peter D.</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Kelliher</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Kee</surname><given-names>Barbara L.</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Pandolfi</surname><given-names>Pier Paolo</given-names></name><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Kappes</surname><given-names>Dietmar</given-names></name><xref ref-type="aff" rid="A13">13</xref></contrib><contrib contrib-type="author"><name><surname>Gounari</surname><given-names>Fotini</given-names></name><xref ref-type="aff" rid="A14">14</xref></contrib><contrib contrib-type="author"><name><surname>Petrie</surname><given-names>Howard</given-names></name><xref ref-type="aff" rid="A15">15</xref></contrib><contrib contrib-type="author"><name><surname>Van der Meulen</surname><given-names>Joni</given-names></name><xref ref-type="aff" rid="A16">16</xref></contrib><contrib contrib-type="author"><name><surname>Speleman</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="A16">16</xref></contrib><contrib contrib-type="author"><name><surname>Paietta</surname><given-names>Elisabeth</given-names></name><xref ref-type="aff" rid="A17">17</xref><xref ref-type="aff" rid="A18">18</xref></contrib><contrib contrib-type="author"><name><surname>Racevskis</surname><given-names>Janis</given-names></name><xref ref-type="aff" rid="A17">17</xref><xref ref-type="aff" rid="A18">18</xref></contrib><contrib contrib-type="author"><name><surname>Wiernik</surname><given-names>Peter H.</given-names></name><xref ref-type="aff" rid="A17">17</xref><xref ref-type="aff" rid="A18">18</xref></contrib><contrib contrib-type="author"><name><surname>Rowe</surname><given-names>Jacob M.</given-names></name><xref ref-type="aff" rid="A19">19</xref></contrib><contrib contrib-type="author"><name><surname>Soulier</surname><given-names>Jean</given-names></name><xref ref-type="aff" rid="A20">20</xref><xref ref-type="aff" rid="A21">21</xref></contrib><contrib contrib-type="author"><name><surname>Avran</surname><given-names>David</given-names></name><xref ref-type="aff" rid="A20">20</xref><xref ref-type="aff" rid="A21">21</xref></contrib><contrib contrib-type="author"><name><surname>Cavé</surname><given-names>Hélène</given-names></name><xref ref-type="aff" rid="A22">22</xref></contrib><contrib contrib-type="author"><name><surname>Dastugue</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="A23">23</xref></contrib><contrib contrib-type="author"><name><surname>Raimondi</surname><given-names>Susana</given-names></name><xref ref-type="aff" rid="A24">24</xref></contrib><contrib contrib-type="author"><name><surname>Meijerink</surname><given-names>Jules P.P.</given-names></name><xref ref-type="aff" rid="A25">25</xref></contrib><contrib contrib-type="author"><name><surname>Cordon-Cardo</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Califano</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A26">26</xref></contrib><contrib contrib-type="author"><name><surname>Ferrando</surname><given-names>Adolfo A.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib></contrib-group><aff id="A1"><label>1</label> Institute for Cancer Genetics, Columbia University, New York, NY, USA</aff><aff id="A2"><label>2</label> Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium</aff><aff id="A3"><label>3</label> Center for Human Genetics, K. U. Leuven, Leuven, Belgium</aff><aff id="A4"><label>4</label> Department of Pathology, Columbia University Medical Center, New York, NY, USA</aff><aff id="A5"><label>5</label> Department of Pediatrics, Columbia University Medical Center, New York, NY, USA</aff><aff id="A6"><label>6</label> Biomarkers and Susceptibility Unit, Catalan Institute of Oncology, IDIBELL, L’Hospitalet, Barcelona, Spain</aff><aff id="A7"><label>7</label> Biomedical Research Centre Network for Epidemiology and Public Health, Catalan Institute of Oncology, IDIBELL, L'Hospitalet, Barcelona, Spain</aff><aff id="A8"><label>8</label> Department of Molecular Genetics, Albert Einstein College of Medicine, Bronx, NY, USA</aff><aff id="A9"><label>9</label> The Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA</aff><aff id="A10"><label>10</label> Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA</aff><aff id="A11"><label>11</label> Department of Pathology, University of Chicago, Chicago, IL, USA</aff><aff id="A12"><label>12</label> Departments of Medicine and Pathology, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA, USA</aff><aff id="A13"><label>13</label> Fox Chase Cancer Center, Philadelphia, PA, USA</aff><aff id="A14"><label>14</label> Department of Medicine, University of Chicago, Chicago, IL, USA</aff><aff id="A15"><label>15</label> Department of Cancer Biology, The Scripps Research Institute, Jupiter, FL, USA</aff><aff id="A16"><label>16</label> Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium</aff><aff id="A17"><label>17</label> Montefiore Medical Center-North Division, New York, NY, USA</aff><aff id="A18"><label>18</label> New York Medical College, New York, NY, USA</aff><aff id="A19"><label>19</label> Rambam Medical Center and Technion, Israel Institute of Technology, Haifa, Israel</aff><aff id="A20"><label>20</label> APHP Hematology Laboratory and INSERM U944, Hôpital Saint-Louis, Paris, France</aff><aff id="A21"><label>21</label> Université Paris 7-Denis Diderot, Institut Universitaire d’Hematology (IUH), Hopital Saint-Louis, Paris, France</aff><aff id="A22"><label>22</label> AP-HP, Hôpital Robert Debré, Departement de Génétique; Université Paris 7-Denis Diderot, Paris, France</aff><aff id="A23"><label>23</label> Laboratoire d'Hématologie, Hôpital Purpan, Toulouse, France</aff><aff id="A24"><label>24</label> Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA</aff><aff id="A25"><label>25</label> Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands</aff><aff id="A26"><label>26</label> Joint Centers for Systems Biology, Columbia University, New York, NY, USA</aff><author-notes><corresp id="FN1">Contact Information: Adolfo A. Ferrando, Assistant Professor of Pediatrics and Pathology, Institute for Cancer Genetics, Columbia University Medical Center, 1130 St Nicholas Ave. ICRC-402A, New York, NY, 10032, Phone: 212-851-4611, FAX: 212-851-5256, <email>af2196@columbia.edu</email></corresp><fn id="FN2" fn-type="equal"><label>*</label><p><text><SENT sid="1" pm="."><plain>These authors contributed equally to this work </plain></SENT>
</text></p></fn><fn id="FN3" fn-type="present-address"><label>†</label><p><text><SENT sid="2" pm="."><plain>Current address: Andalusian Stem Cell Bank, Centro de Investigacion Biomedica, Granada, Spain. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>22</day><month>9</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>24</day><month>10</month><year>2010</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2010</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>5</month><year>2011</year></pub-date><volume>16</volume><issue>11</issue><fpage>1321</fpage><lpage>1327</lpage><permissions><license><license-p>Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p></license></permissions><abstract><p id="P1"><SecTag type="ABS"><text><SENT sid="3" pm="."><plain>The TLX1 transcription factor oncogene plays an important role in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL). </plain></SENT>
<SENT sid="4" pm="."><plain>However, the specific mechanisms of T-cell transformation downstream of TLX1 remain to be elucidated. </plain></SENT>
<SENT sid="5" pm="."><plain>Here we show that forced expression of TLX1 in transgenic mice induces T-ALL tumors with frequent deletions and mutations in Bcl11b, and identify the presence of recurrent mutations and deletions in BCL11B in 16% of human T-ALLs. </plain></SENT>
<SENT sid="6" pm="."><plain>Most notably, mouse TLX1 tumors were typically aneuploid and showed a marked defect in the activation of the mitotic checkpoint. </plain></SENT>
<SENT sid="7" pm="."><plain>Mechanistically, TLX1 directly downregulates the expression of CHEK1 and additional mitotic control genes and induces loss of the mitotic checkpoint in non transformed preleukemic thymocytes. </plain></SENT>
<SENT sid="8" pm="."><plain>These results identify a novel mechanism contributing to chromosomal missegregation and aneuploidy active at the earliest stages of tumor development in the pathogenesis of cancer. </plain></SENT>
</text></SecTag></p></abstract></article-meta></front><body><p id="P2"><text><SENT sid="9" pm="."><plain>T-ALL is an aggressive hematologic tumor resulting from the malignant transformation of T-cell progenitors. </plain></SENT>
<SENT sid="10" pm="."><plain>The TLX1 transcription factor oncogene is translocated and aberrantly expressed in 5% to 10% of pediatric and up to 30% of adult T-ALL cases1–4. </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, TLX3, a highly related TLX family member, is overexpressed as result of the t(5;14)(q35;q32) translocation in about 25% of pediatric TALLs and in 5% of adult T-ALL cases5. TLX1 expression defines a distinct molecular group of T-ALL characterized by a differentiation block at the early cortical stage of thymocyte development2 and favorable prognosis1,2,6. </plain></SENT>
<SENT sid="12" pm="."><plain>Moreover, TLX1 and TLX3 leukemias seem to constitute a distinct oncogenic group with specific genetic alterations rarely found in non-TLX induced T-ALLs including the rearrangement of the NUP214-ABL1 oncogene7 and mutations in the WT18 and PHF69 tumor suppressor genes. </plain></SENT>
<SENT sid="13" pm="."><plain>However, little is known about the specific mechanisms that mediate T-cell transformation downstream of TLX1. </plain></SENT>
<SENT sid="14" pm="."><plain>To address this question we have used an integrative genomic approach to characterize the transcriptional programs and oncogenic pathways active in human and mouse TLX1-induced leukemia. </plain></SENT>
</text></p><SecTag type="RESULTS"><sec sec-type="results" id="S1"><title><text><SENT sid="15" pm="."><plain>RESULTS </plain></SENT>
</text></title><sec id="S2"><title><text><SENT sid="16" pm="."><plain>T-ALL development in TLX1 transgenic mice </plain></SENT>
</text></title><p id="P3"><text><SENT sid="17" pm="."><plain>In order to investigate the mechanisms of T-cell transformation driven by TLX1, we generated p56Lck-TLX1 transgenic mice in which the Lck proximal promoter drives expression of TLX1 in T-cell progenitors10,11. TLX1 transgenic mice from three founder lines showed accelerated mortality due to the development of lymphoid tumors with a median latency of 27, 32 or 46 weeks, respectively (P&lt;0.0001) (Fig. 1a). </plain></SENT>
<SENT sid="18" pm="."><plain>Tumor-bearing mice showed enlarged thymi populated by immature lymphoblasts and leukemic infiltration of bone marrow and peripheral organs including lymph nodes, spleen, liver and kidneys (Fig. 1b). </plain></SENT>
<SENT sid="19" pm="."><plain>Overall, 92% of TLX1 transgenic animals developed tumors at 52 weeks. TLX1-induced leukemias showed high levels of TLX1 protein (Fig. 1c–d) and expression of CD3 indicative of a T-cell phenotype (Fig. 1e). </plain></SENT>
<SENT sid="20" pm="."><plain>Moreover, flow cytometry analysis demonstrated the expression of CD4 and CD8 in most tumors (Fig. 1f–g). </plain></SENT>
<SENT sid="21" pm="."><plain>In addition, this analysis revealed significant heterogeneity in these leukemias with 53% of the tumors showing two or more immunophenotypically different cell populations (Fig. 1f). </plain></SENT>
<SENT sid="22" pm="."><plain>Finally, TLX1-induced tumors showed clonal expression of a single TCRB chain in 4/5 tumors examined and only 2 TCRB chains in the remaining sample (Fig. 1h), indicating that despite their heterogeneous immunophenotypes these are monoclonal T-cell tumors. </plain></SENT>
</text></p></sec><sec id="S3"><title><text><SENT sid="23" pm="."><plain>Mouse and human TLX-induced T-ALLs have a common expression signature </plain></SENT>
</text></title><p id="P4"><text><SENT sid="24" pm="."><plain>To address the transcriptional programs activated in mouse TLX1 leukemias, we analyzed the expression profiles of mouse tumors from TLX1 transgenics (n=6) and of T-ALLs generated by retroviral insertional mutagenesis or arising in the context of different T-ALL transgenic and knockout models including Tal1, Lmo2 and Olig2/Bhlhb1 transgenics and Tcf3/E2A, Trp53 and Pten knockouts (n=49) (Supplementary Table 1). </plain></SENT>
<SENT sid="25" pm="."><plain>Significant differentially expressed genes were calculated by Comparative Marker Selection Genepattern tool12 using t-test statistical test and non-parametric P value calculation (1,000 random permutations). </plain></SENT>
<SENT sid="26" pm="."><plain>This analysis revealed that TLX1 tumors are characterized by a distinct gene expression signature with upregulation of 114 genes and downregulation of 377 transcripts (Fold change &gt;2, P &lt;0.005) (Fig. 2a; Supplementary Table 2). </plain></SENT>
<SENT sid="27" pm="."><plain>Moreover, Gene Set Enrichment Analysis (GSEA) of human T-ALL (n=82) using these mouse TLX1-signature genes showed significant enrichment in human TLX1 and TLX3 tumors (P&lt;0.001)(Fig. 2b; Supplementary Table 3), highlighting the relevance of our mouse model for the analysis of TLX-induced transformation. </plain></SENT>
</text></p></sec><sec id="S4"><title><text><SENT sid="28" pm="."><plain>TLX1 expression blocks T-cell development and induces apoptosis </plain></SENT>
</text></title><p id="P5"><text><SENT sid="29" pm="."><plain>Next, we decided to explore the effects and mechanistic role of TLX1-expression in T-cell progenitors in young TLX1 transgenic mice prior to the development of T-ALL. </plain></SENT>
<SENT sid="30" pm="."><plain>Analysis of TLX1-transgenic mice at 3 and 6 weeks of age showed a drastic reduction in thymic size and cellularity compared with littermate controls (Fig. 3a), but no clear defects in cell proliferation (Fig. 3b). </plain></SENT>
<SENT sid="31" pm="."><plain>Flow cytometry analysis of thymocyte differentiation markers in TLX1 transgenic animals and littermate controls showed a defect in T-cell development with arrest at the double negative 2 (DN2) stage of thymocyte differentiation (Fig. 3c), which was accompanied by a marked increase in apoptosis (Fig. 3d,e). </plain></SENT>
<SENT sid="32" pm="."><plain>Consistent with these results, transgenic expression of BCL2 in Lck-TLX1 VavP-BCL2 double transgenic mice abrogated apoptosis (Fig. 3f) and rescued the defect in thymus size (Fig. 3g) and cellularity (Fig. 3h) observed in preleukemic TLX1-transgenic mice. </plain></SENT>
</text></p></sec><sec id="S5"><title><text><SENT sid="33" pm="."><plain>Secondary mutations in the pathogenesis of TLX1-induced T-ALL </plain></SENT>
</text></title><p id="P6"><text><SENT sid="34" pm="."><plain>The prolonged latency in the development of T-ALL in TLX1 transgenic mice and the clonal nature of these tumors prompted us to investigate the presence of cooperating mutations involved in the pathogenesis of TLX1-induced leukemias. </plain></SENT>
<SENT sid="35" pm="."><plain>Activating mutations in NOTCH1 are present in over 50% of human T-ALLs13,14. </plain></SENT>
<SENT sid="36" pm="."><plain>Similarly, prototypical mutations in Notch1 were present in 3/25 (12%) TLX1-induced mouse tumors (Supplementary Table 4). </plain></SENT>
<SENT sid="37" pm="."><plain>Moreover, array Comparative Genomic Hybridization (aCGH) analysis revealed the presence of recurrent numerical and structural chromosomal alterations in these tumors (Fig. 4a, Supplementary Fig. 1). </plain></SENT>
<SENT sid="38" pm="."><plain>Thus, focal homozygous deletions affecting the Pten tumor suppressor gene were present in 4/15 (27%) samples (Fig. 4a, Supplementary Fig. 1, Supplementary Table 5). </plain></SENT>
<SENT sid="39" pm="."><plain>In addition, immunohistochemical analysis of Pten showed loss of Pten protein expression in 11/24 (42%) tumors (Supplementary Fig. 1). </plain></SENT>
<SENT sid="40" pm="."><plain>Notably, PTEN deletions, mutations and loss of PTEN protein expression have been reported in 20% of human T-ALLs15,16. </plain></SENT>
<SENT sid="41" pm="."><plain>Chromosomal deletions involving Trp53 and Ikzf1, which are sporadically mutated and deleted in human T-ALLs17,18, were detected in one tumor each (Fig. 4a, Supplementary Fig.1, Supplementary Table 5). </plain></SENT>
<SENT sid="42" pm="."><plain>In addition three mouse TLX1 T-ALL samples harbored heterozygous deletions in chromosome 12 with a common deleted region containing only the Bcl11b gene (Fig. 4a–c, Supplementary Table 5). </plain></SENT>
<SENT sid="43" pm="."><plain>Moreover, DNA sequence analysis of Bcl11b showed the presence of Bcl11b mutations in 4/15 (27%) mouse TLX1-induced T-ALLs (Fig. 4d–e, Supplementary Table 6), which together with the 3 Bcl11b deletions identified in our aCGH analysis brings the prevalence of Bcl11b alterations in mouse TLX1-induced tumors to 7/15 (47%). </plain></SENT>
<SENT sid="44" pm="."><plain>Notably, mutation analysis of Bcl11b in T-ALL tumors occurring in Pten knockout animals (n=6), Trp53 knockout mice (n=2), Ctnnb1 transgenic animals (n=4) or induced by retroviral insertional mutagenesis (n=9) failed to detect any Bcl11b mutations in these non-TLX1 transgenic tumors (Fisher’s exact test P &lt;0.001). </plain></SENT>
</text></p></sec><sec id="S6"><title><text><SENT sid="45" pm="."><plain>Recurrent deletions and mutations in BCL11B in human T-ALL </plain></SENT>
</text></title><p id="P7"><text><SENT sid="46" pm="."><plain>Bcl11b encodes a zinc finger transcription factor with a critical role in the differentiation and survival of T-cell progenitors in the thymus19,20. </plain></SENT>
<SENT sid="47" pm="."><plain>Given the similarities between our mouse model of TLX1-induced leukemia and human T-ALL, we hypothesized that BCL11B alterations could also be implicated in the pathogenesis of human T-ALL. </plain></SENT>
<SENT sid="48" pm="."><plain>Most notably, aCGH analysis of human T-ALL samples showed the presence of focal heterozygous deletions encompassing the BCL11B locus in 2/69 (3%) T-ALL cases (Fig. 5a). </plain></SENT>
<SENT sid="49" pm="."><plain>In addition, mutation analysis of BCL11B in human T-ALL demonstrated the presence of truncating frameshift mutations and missense point mutations in 9/71 (13%) cases analyzed (Fig. 5b). </plain></SENT>
<SENT sid="50" pm="."><plain>Interestingly, all 6 BCL11B missense mutations involved zinc finger domains (Fig. 5b). </plain></SENT>
<SENT sid="51" pm="."><plain>One sample showed compound heterozygous BCL11B mutations while the remaining 5 cases harbored heterozygous BCL11B lesions (Supplementary Table 7). </plain></SENT>
<SENT sid="52" pm="."><plain>Notably, sequence analysis of samples obtained at the time of clinical remission demonstrated the somatic origin of BCL11B mutations in all 6 cases with available material (Fig. 5c). </plain></SENT>
<SENT sid="53" pm="."><plain>Finally, expression analysis of TLX1 or TLX3 in 8 T-ALLs harboring mutations or deletions in BCL11B with RNA available showed aberrant expression of these transcription factor oncogenes in 5/8 (63%) [TLX1 (4/8); TLX3 (1/8)] of these samples (Supplementary Table 7). </plain></SENT>
<SENT sid="54" pm="."><plain>Altogether, these results identify BCL11B as a tumor suppressor gene recurrently deleted and mutated in human T-ALL. </plain></SENT>
</text></p></sec><sec id="S7"><title><text><SENT sid="55" pm="."><plain>Interaction between BCL11B and TLX1 in T-cell transformation </plain></SENT>
</text></title><p id="P8"><text><SENT sid="56" pm="."><plain>The identification of a high prevalence of Bcl11b mutations and deletions in TLX1-induced tumors suggest a specific genetic interaction between these two genes in T-cell transformation. </plain></SENT>
<SENT sid="57" pm="."><plain>To test if BCL11B could be a direct transcriptional target of TLX1 in T-ALL, we analyzed the binding of TLX1 to the BCL11B promoter via chromatin immunoprecipitation analysis in ALL-SIL, a T-ALL cell line expressing high levels of TLX1 as result of the t(10;14)(q24;q11) translocation21. </plain></SENT>
<SENT sid="58" pm="."><plain>This analysis revealed that indeed TLX1 binds to the BCL11B promoter (Fig. 5d). </plain></SENT>
<SENT sid="59" pm="."><plain>Moreover, siRNA knockdown of TLX1 in this cell line resulted in transcriptional upregulation of BCL11B (Fig. 5e), indicating that BCL11B is a direct transcriptional target downregulated by TLX1 in T-ALL. </plain></SENT>
</text></p></sec><sec id="S8"><title><text><SENT sid="60" pm="."><plain>TLX1 T-ALLs are aneuploid and have a defective mitotic checkpoint </plain></SENT>
</text></title><p id="P9"><text><SENT sid="61" pm="."><plain>In addition to identifying focal areas of amplification and deletion, our aCGH analysis of mouse TLX1 tumors showed gains and losses of whole chromosomes in most samples analyzed, suggesting a high prevalence of numerical chromosomal abnormalities in these leukemias (Fig. 4a, Supplementary Table 8). </plain></SENT>
<SENT sid="62" pm="."><plain>Spectral karyotyping (SKY) analysis confirmed these results and showed the presence of trisomy 15 in 3/4 TLX1 tumor samples analyzed (Fig. 6a, Supplementary Table 8). </plain></SENT>
<SENT sid="63" pm="."><plain>Overall, 78% (14/18) of TLX1-induced leukemias showed chromosomal gains and losses, with 67% (12/18) harboring trisomy 15 (alone or in combination with trisomy 17, gain of chromosome Y, monosomy X or hyperdiploidy) (Fig. 6b, Supplementary Table 8). </plain></SENT>
<SENT sid="64" pm="."><plain>Previous in vitro studies had associated TLX1 with alterations in the G2/M cell cycle checkpoint22 and forced expression of TLX1 can induce aneuploidy in B-cells after disruption of the mitotic spindle23. </plain></SENT>
<SENT sid="65" pm="."><plain>To test the function of the mitotic checkpoint in our TLX1-induced leukemias we treated TLX1-T-ALL lymphoblasts with taxol, which impairs microtubule remodeling. </plain></SENT>
<SENT sid="66" pm="."><plain>This analysis revealed that TLX1 mouse T-ALL lymphoblasts fail to arrest in mitosis following disruption of the mitotic spindle (Fig. 6c). </plain></SENT>
<SENT sid="67" pm="."><plain>In contrast, tumors induced by the TAL1, TAL1 plus LMO1, TAL1 plus LMO2 and NUP214-ABL1 T-ALL oncogenes showed a marked accumulation of cells in mitosis after taxol treatment (Fig. 6c, Supplementary Fig. 2). </plain></SENT>
<SENT sid="68" pm="."><plain>Similar results were obtained using nocodazole, which disrupts tubulin polymerization (Fig. 6c), and BrdU incorporation analysis verified that TLX1 mouse tumors proliferate and fail to arrest in M phase following disruption of the mitotic spindle (Supplementary Fig.3). </plain></SENT>
</text></p></sec><sec id="S9"><title><text><SENT sid="69" pm="."><plain>TLX1 directly downregulates mitotic genes in T-cell transformation </plain></SENT>
</text></title><p id="P10"><text><SENT sid="70" pm="."><plain>The acquisition of chromosomal instability may represent an early event in the pathogenesis of cancer24. </plain></SENT>
<SENT sid="71" pm="."><plain>To investigate the specific mechanisms involved in the earliest stages of TLX1-induced transformation, we performed microarray gene expression analysis of sorted preleukemic DN2 cells from 3 week old mice. </plain></SENT>
<SENT sid="72" pm="."><plain>Significant differentially expressed genes were calculated by Comparative Marker Selection Genepattern tool12 as described above. </plain></SENT>
<SENT sid="73" pm="."><plain>This analysis revealed marked differences in gene expression in TLX1 transgenic thymocytes and DN2 cells from normal littermate controls with 175 genes upregulated and 138 genes downregulated in TLX1-expressing cells (Fold change &gt; 1.5, P&lt;0.005) (Supplementary Table 9). </plain></SENT>
<SENT sid="74" pm="."><plain>Next, and to specifically address the role of direct TLX1 target genes in T-cell transformation, we performed ChIP-chip analysis of TLX1 in ALL-SIL cells. </plain></SENT>
<SENT sid="75" pm="."><plain>In these experiments, TLX1 chromatin immunoprecipitates were hybridized to human proximal promoter arrays and analyzed using ChIP-chip Significance Analysis (CSA) to identify high confidence TLX1 direct target genes25. </plain></SENT>
<SENT sid="76" pm="."><plain>This analysis identified 5,549 promoters bound by TLX1 with a significance cutoff of P&lt;0.0001 (Supplementary Table 10). </plain></SENT>
<SENT sid="77" pm="."><plain>Integration of these ChIP-chip results with the gene expression signature associated with aberrant expression of TLX1 in T-cell progenitors revealed a marked enrichment of TLX1 direct target genes involved in mitosis (P &lt;0.001) (Supplementary Table 11) downregulated in TLX1-preleukemic cells (Fig.6d and Supplementary Fig. 4). </plain></SENT>
<SENT sid="78" pm="."><plain>Notably, these included CHEK1, a key regulator of the mitotic spindle checkpoint and one of the genes most consistently downregulated in both mouse and human TLX-induced leukemias (Supplementary Tables 2 and 3). </plain></SENT>
<SENT sid="79" pm="."><plain>Consistent with these results, TLX1-knockdown in ALL-SIL cells resulted in transcriptional upregulation of CHEK1 (Fig.6g) and pharmacologic inhibition of CHEK1 in human TALL cell lines abrogated the activation of the mitotic checkpoint upon treatment with taxol (Supplementary Fig. 5). </plain></SENT>
<SENT sid="80" pm="."><plain>These results suggest a mechanistic role of TLX1 in the control of cell cycle checkpoint genes at the earliest stages of T-cell transformation. </plain></SENT>
</text></p><p id="P11"><text><SENT sid="81" pm="."><plain>To test if TLX1 expression can induce a defective mitotic checkpoint phenotype in preleukemic cells we isolated viable thymocytes from TLX1-BCL2 double transgenic mice and compared them with cells obtained from BCL2 transgenic controls. </plain></SENT>
<SENT sid="82" pm="."><plain>This experiment showed a marked defect in the activation of the mitotic checkpoint after taxol treatment in TLX1-BCL2 preleukemic cells compared with BCL2 controls (Fig. 6h). </plain></SENT>
<SENT sid="83" pm="."><plain>The polyclonal/non transformed nature of TLX1-BCL2 preleukemic cells was verified by RT-PCR analysis of TCRB expression (Supplementary Fig. 6). </plain></SENT>
<SENT sid="84" pm="."><plain>Overall, these results demonstrate that the impaired control of the mitotic checkpoint in TLX1-transgenic mice is an early event in tumor formation that precedes clonal selection in T-cell transformation. </plain></SENT>
</text></p></sec><sec id="S10"><title><text><SENT sid="85" pm="."><plain>Chromosomal alterations in human TLX-induced leukemias </plain></SENT>
</text></title><p id="P12"><text><SENT sid="86" pm="."><plain>Overall the results described above support a direct mechanistic role for TLX1 in the induction of chromosomal missegregation suggesting that similar mechanisms may operate in the pathogenesis of human leukemias. </plain></SENT>
<SENT sid="87" pm="."><plain>Most notably, and consistent with this thesis, the TLX1-positive ALL-SIL cell line showed a selective defect in the mitotic checkpoint (Supplementary Fig. 2). </plain></SENT>
<SENT sid="88" pm="."><plain>In addition, karyotype analysis of a series of 57 well characterized pediatric T-ALLs2 demonstrated a higher frequency of aneuploid karyotypes (8/13, 62%) in TLX1 and TLX3 positive human T-cell tumors compared with other genetic subgroups of T-ALL (5/44, 11%) (Fisher’s exact test P &lt;0.001) (Supplementary Table 12). </plain></SENT>
<SENT sid="89" pm="."><plain>Moreover, analysis of an independent series of 229 T-ALLs showed a marked predominance of numerical chromosomal abnormalities in TLX1 and TLX3 positive T-ALLs (aneuploidy/pseudodiploid karyotype ratios: 6/1 for TLX1 tumors; 10/10 for TLX3 leukemias and 24/63 for non-TLX T-ALLs; Fisher’s exact test P &lt;0.004 for TLX1 vs. non-TLX; P &lt;0.05 for TLX3 vs. non-TLX and P &lt;0.003 for TLX1/TLX3 vs. non-TLX) (Supplementary Table 13). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="S11"><title><text><SENT sid="90" pm="."><plain>Discussion </plain></SENT>
</text></title><p id="P13"><text><SENT sid="91" pm="."><plain>TLX1 plays a central role in the pathogenesis of T-ALL. </plain></SENT>
<SENT sid="92" pm="."><plain>However the elucidation of the specific mechanisms that mediate T-cell transformation downstream of TLX1 has been hampered by the lack of an animal model of TLX1-induced T-ALL and by the lack of understanding of the direct transcriptional targets controlled by TLX1 in human leukemia. </plain></SENT>
<SENT sid="93" pm="."><plain>Here we demonstrate that TLX1 transgenic mice develop clonal immature T-cell tumors highly related to human TLX1 and TLX3 TALLs in their clinical presentation and gene expression signatures. </plain></SENT>
<SENT sid="94" pm="."><plain>The extended latency in the development of leukemia in this model and the clonal nature of TLX1-induced tumors suggest that TLX1 overexpression in the thymus is not sufficient for malignant transformation of T-cell progenitor cells. </plain></SENT>
<SENT sid="95" pm="."><plain>This thesis is further supported by the identification of recurrent cooperating mutations and chromosomal abnormalities in mouse TLX1-induced leukemias. </plain></SENT>
<SENT sid="96" pm="."><plain>Most notably, TLX1-induced tumors harbored recurrent alterations in oncogenes (Notch1) and tumor suppressor genes (Pten, Cdkn2a) frequently mutated in human T-ALL13–15,26. </plain></SENT>
<SENT sid="97" pm="."><plain>In addition this analysis revealed the presence of recurrent mutations and deletions centered on the Bcl11b locus in 47% of mouse TLX1-induced tumors analyzed. </plain></SENT>
<SENT sid="98" pm="."><plain>Based on these results, we hypothesized that BCL11B could play a tumor suppressor role in human leukemia and identified recurrent deletions and mutations in this gene in 16% of human TALLs. </plain></SENT>
<SENT sid="99" pm="."><plain>Notably, most BCL11B alterations found in mouse TLX1-induced tumors and in human T-ALLs were heterozygous and loss of one copy of Bcl11b in mice accelerates the development of thymic lymphomas after γ-irradiation or in Trp53 heterozygous mice without loss of the wild type Bcl11b allele27. </plain></SENT>
<SENT sid="100" pm="."><plain>Finally, ChIP and expression analysis demonstrated that BCL11B is a direct transcriptional target downregulated by TLX1 in T-ALL. </plain></SENT>
<SENT sid="101" pm="."><plain>The model that emerges from these results is that aberrant expression of TLX1 partially downregulates the BCL11B tumor suppressor gene during T-cell transformation and that this negative transcriptional regulatory axis is fixed and reinforced by secondary genetic alterations in the BCL11B locus acquired during tumor progression. </plain></SENT>
<SENT sid="102" pm="."><plain>Strikingly, PHF6 and WT1, two additional tumor suppressor genes frequently mutated in TLX1-induced T-ALL are also among the TLX1 targets identified in our ChIP-on-chip analysis (Supplementary Table 10), suggesting that this model could also apply to these TLX1-target tumor suppressor genes. </plain></SENT>
</text></p><p id="P14"><text><SENT sid="103" pm="."><plain>Perhaps the most striking finding in TLX1-induced leukemias was the presence of a very high incidence of numerical chromosomal alterations in these tumors, indicating that alterations in the mitotic machinery could play an important role in TLX1-induced transformation. </plain></SENT>
<SENT sid="104" pm="."><plain>Consistent with this model, our results demonstrate that TLX1-induced T-ALLs have a defective mitotic checkpoint and fail to arrest in mitosis upon treatment with taxol or nocodazole. </plain></SENT>
<SENT sid="105" pm="."><plain>Moreover, this mitotic checkpoint defect is readily present in preleukemic thymocytes from TLX1 transgenic mice, suggesting that aneuploidy represents a direct effect of TLX1 overexpression and an early event in the genesis of mouse TLX1-induced tumors. </plain></SENT>
</text></p><p id="P15"><text><SENT sid="106" pm="."><plain>Mechanistically, analysis of TLX1 direct target genes in the context of TLX1 preleukemic thymocytes revealed that multiple TLX1 direct target genes involved in mitosis and chromosomal segregation are downregulated in T-cell progenitor cells isolated from TLX1 transgenic mice. </plain></SENT>
<SENT sid="107" pm="."><plain>Among these, CHEK1, a critical checkpoint regulator, is downregulated in mouse and human TLX-induced leukemias and could have a particularly prominent role in the loss of the mitotic checkpoint downstream of TLX1. </plain></SENT>
<SENT sid="108" pm="."><plain>However, it would be deceiving to attribute the induction of aneuploidy by TLX1 to the dysregulation of a single gene, as multiple transcripts with prominent roles in mitosis seem to be controlled by TLX1 in T-cells. </plain></SENT>
<SENT sid="109" pm="."><plain>In addition, a transcription independent effect of TLX1 in the control of cell cycle via interaction with the PP2A phosphatase has been proposed22. </plain></SENT>
</text></p><p id="P16"><text><SENT sid="110" pm="."><plain>Overall, our results mechanistically link the aberrant expression of TLX1 with the development of chromosomal instability at the earliest stages of T-cell transformation and illustrate the power of integrative genomic analyses of mouse and human tumors to elucidate basic mechanisms and oncogenic pathways involved in tumor initiation and disease progression. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="S12"><title><text><SENT sid="111" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="S13"><title><text><SENT sid="112" pm="."><plain>Transgenic mice </plain></SENT>
</text></title><p id="P17"><text><SENT sid="113" pm="."><plain>The human TLX1 cDNA was amplified by PCR using BamHI restriction site containing primers and cDNA of the human T-cell leukemia cell line ALL-SIL as template and was cloned in the pUC1017 vector, downstream of the mouse T-cell specific p56Lck proximal promoter. </plain></SENT>
<SENT sid="114" pm="."><plain>C57BL/6J VavP-Bcl2 transgenic mice have been described before 28,29. </plain></SENT>
<SENT sid="115" pm="."><plain>Animal experiments were performed under the supervision of the Columbia University Medical Center IACUC. </plain></SENT>
</text></p></sec><sec id="S14"><title><text><SENT sid="116" pm="."><plain>Gene expression profiling of mouse tumors </plain></SENT>
</text></title><p id="P18"><text><SENT sid="117" pm="."><plain>We profiled a cohort of 6 TLX1 transgenic-derived TALLs and additional 49 T-cell lymphoblastic tumors from different genetic models of T-ALL (see Supplementary Table 1 for details on the genetic background of tumors analyzed). </plain></SENT>
<SENT sid="118" pm="."><plain>Gene-expression profiling was performed using Affymetrix Mouse Genome 430A 2.0 Array following standard procedures. </plain></SENT>
<SENT sid="119" pm="."><plain>Raw data is available in GEO (accession number GSE19499). </plain></SENT>
<SENT sid="120" pm="."><plain>Array normalization was performed by DNA-Chip-Analyzer (dChip)30. </plain></SENT>
<SENT sid="121" pm="."><plain>Following interarray normalization we preprocessed and analyzed the microarray data for differential expression using the Genepattern platform for microarray analysis31. </plain></SENT>
</text></p></sec><sec id="S15"><title><text><SENT sid="122" pm="."><plain>Gene expression profiling human T-ALL </plain></SENT>
</text></title><p id="P19"><text><SENT sid="123" pm="."><plain>Affymetrix gene expression data from pediatric T-ALL samples has been reported before (GEO accession # GSE10609)32. </plain></SENT>
<SENT sid="124" pm="."><plain>This series encompasses 7 TLX1 positive cases, 23 TLX3 positive samples and 53 other T-ALLs including 33 tumors with aberrant expression of TAL1 and LMO2. </plain></SENT>
<SENT sid="125" pm="."><plain>Tumors with high levels of expression of HOXA9 constitute a heterogeneous molecular group resulting from translocations involving the HOXA loci, aberrant expression of CALM-AF10, SET-NUP214 and MLL fusion oncogenes and were a priory excluded from this series. </plain></SENT>
<SENT sid="126" pm="."><plain>Enrichment of the TLX1 direct target genes identified by ChIP-chip (P &lt;10−4) in the TLX1 and TLX3 class signature was analyzed by GSEA using the signal-to-noise metric and a 1,000 permutations of the class labels. </plain></SENT>
</text></p></sec><sec id="S16"><title><text><SENT sid="127" pm="."><plain>Gene expression profiling of normal and TLX1 transgenic thymocytes </plain></SENT>
</text></title><p id="P20"><text><SENT sid="128" pm="."><plain>We isolated single cell suspensions of thymi from 3 week old wild type and TLX1 transgenic littermates and isolated CD4− CD8− CD44+CD25+ cells on a FACS ARIA Sorter (Beckton Dickinson). </plain></SENT>
<SENT sid="129" pm="."><plain>We collected cells in RLT buffer (Qiagen) and extracted RNA with the RNeasy mini kit (Qiagen). </plain></SENT>
<SENT sid="130" pm="."><plain>We verified RNA quantity and quality on a Nanodrop spectrophotometer and an Agilent Bioanalyzer 2100, respectively. </plain></SENT>
<SENT sid="131" pm="."><plain>We used the Ovation RNA Amplification System V2 (NuGEN) to generate amplified cDNA, which was subsequently fragmented and labeled with the FL-Ovation cDNA Biotin Module V2 (NuGEN) and hybridized on Mouse Genome 430 2.0 Arrays (Affymetrix). </plain></SENT>
</text></p><p id="P21"><text><SENT sid="132" pm="."><plain>Array normalization and data analysis was performed as described above. </plain></SENT>
<SENT sid="133" pm="."><plain>Significant differentially expressed genes were calculated by the Comparative Marker Selection Genepattern tool using t-test statistical test with an asymptotic P value and zero permutations. </plain></SENT>
</text></p><p id="P22"><text><SENT sid="134" pm="."><plain>For enrichment analysis of mitotic genes controlled by TLX1 in preleukemic cells, we first identified 155 mitotic regulators (GO:0000278~mitotic cell cycle) within the top 5,549 TLX1 targets identified by ChIP-chip (P&lt; 0.0001) using the DAVID (<ext-link ext-link-type="uri" xlink:href="http://david.abcc.ncifcrf.gov/">http://david.abcc.ncifcrf.gov/</ext-link>) Functional Annotation tool, and used this geneset to run GSEA in TLX1 transgenic versus wild type DN2 cells test using the signal-to-noise metric and 1,000 permutations of the gene list. </plain></SENT>
</text></p></sec><sec id="S17"><title><text><SENT sid="135" pm="."><plain>Array comparative genomic hybridization (aCGH) </plain></SENT>
</text></title><p id="P23"><text><SENT sid="136" pm="."><plain>We performed aCGH analysis of mouse tumors using the Mouse Genome CGH 244A platform (Agilent Technologies) according to the instructions of the manufacturer. </plain></SENT>
<SENT sid="137" pm="."><plain>To analyze these data we used DNA Analytics 4.0 software (Agilent Technologies). </plain></SENT>
<SENT sid="138" pm="."><plain>For Array-CGH analysis of human T-ALLs we used SurePrint G3 Human CGH 1x1M Oligo Microarrays (Agilent Technologies). </plain></SENT>
<SENT sid="139" pm="."><plain>We analyzed human array CGH data with the Genomic Workbench 5.0.14 software (Agilent Technologies). </plain></SENT>
</text></p></sec><sec id="S18"><title><text><SENT sid="140" pm="."><plain>Mitotic checkpoint analysis </plain></SENT>
</text></title><p id="P24"><text><SENT sid="141" pm="."><plain>Integrity of the mitotic checkpoint was tested by flow cytometry analysis of cell cycle in cells treated with 1 μM taxol (Sigma) (human cell lines), 0.1 μM taxol (mouse cell lines), 100 ng ml−1 nocodazole (Sigma) or vehicle for 24 hours. </plain></SENT>
<SENT sid="142" pm="."><plain>For analysis of the mitotic checkpoint in pre-leukemic mouse cells, thymocytes from 3 week old VavP-Bcl2 and VavP-Bcl2/TLX1 transgenic littermates were cultured on OP9-DL1 cells for 24 hours followed by taxol treatment and cell cycle analysis as described above. </plain></SENT>
</text></p></sec><sec id="S19"><title><text><SENT sid="143" pm="."><plain>TLX1 ChIP-chip analysis </plain></SENT>
</text></title><p id="P25"><text><SENT sid="144" pm="."><plain>We performed ChIP-chip analysis of TLX1 direct target genes in the ALL-SIL T-ALL cell line using a rabbit polyclonal TLX1-specific antibody (C-18, sc-880) (Santa Cruz Biotechnology) using Agilent Human Proximal Promoter Microarrays (244K features/array) as previously described33. </plain></SENT>
<SENT sid="145" pm="."><plain>We identified TLX1 direct targets via ChIP-chip Significance Analysis (CSA) as described before25. </plain></SENT>
</text></p></sec><sec id="S20"><title><text><SENT sid="146" pm="."><plain>Quantitative ChIP Analysis </plain></SENT>
</text></title><p id="P26"><text><SENT sid="147" pm="."><plain>Relative real-time PCR quantitation of promoter sequences was normalized to β-actin levels in chromatin immunoprecipitates performed with a TLX1-specific antibody (C-18 rabbit polyclonal antibody (sc-880), Santa Cruz Biotechnology), or an IgG antibody. </plain></SENT>
<SENT sid="148" pm="."><plain>Primer sequences are listed in Supplementary Table 15. </plain></SENT>
</text></p></sec><sec id="S21"><title><text><SENT sid="149" pm="."><plain>siRNA knockdown </plain></SENT>
</text></title><p id="P27"><text><SENT sid="150" pm="."><plain>In TLX1 siRNA knockdown experiments we electroporated ALL-SIL cells (275V, 1,000 μF) using a Genepulser MXcell electroporator (Biorad) with 200 nM of Silencer Select Negative Control #1 siRNA (Ambion, cat #4390844) or TLX1 siRNA1 (5’-GAUGGAGAGUAACCGCAGAtt-3’). </plain></SENT>
<SENT sid="151" pm="."><plain>Knockdown efficiency was measured by quantitative RT-PCR and Western blot. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="S22"><title><text><SENT sid="152" pm="."><plain>Supplementary Material </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="SD1"><label>1</label><caption><p id="P50"><text><SENT sid="153" pm="."><plain>Supplementary results </plain></SENT>
</text></p><p id="P51"><text><SENT sid="154" pm="."><plain>Supplementary methods </plain></SENT>
</text></p><p id="P28"><text><SENT sid="155" pm="."><plain>Supplementary Figure 1 Numerical and structural chromosomal alterations in TLX-induced mouse T-ALL. </plain></SENT>
</text></p><p id="P29"><text><SENT sid="156" pm="."><plain>Supplementary Figure 2 Mitotic checkpoint analysis in mouse and human T-ALL cells. </plain></SENT>
</text></p><p id="P30"><text><SENT sid="157" pm="."><plain>Supplementary Figure 3 Cell proliferation and disruption of the mitotic spindle in mouse T-ALLs. </plain></SENT>
</text></p><p id="P31"><text><SENT sid="158" pm="."><plain>Supplementary Figure 4 TLX1 downregulates mitotic control genes. </plain></SENT>
</text></p><p id="P32"><text><SENT sid="159" pm="."><plain>Supplementary Figure 5 CHEK1 inhibition impairs the activation of the mitotic checkpoint in T-ALL cells. </plain></SENT>
</text></p><p id="P33"><text><SENT sid="160" pm="."><plain>Supplementary Figure 6 Thymocytes isolated from preleukemic TLX1-transgenic mice are polyclonal. </plain></SENT>
</text></p><p id="P34"><text><SENT sid="161" pm="."><plain>Supplementary Figure 7 TLX1-expression is required for the growth and survival of T- ALL lymphoblasts. </plain></SENT>
</text></p><p id="P35"><text><SENT sid="162" pm="."><plain>Supplementary Table 1 Mouse T-ALL tumors analyzed. </plain></SENT>
</text></p><p id="P36"><text><SENT sid="163" pm="."><plain>Supplementary Table 2 Differentially expressed genes in mouse Tlx1 positive tumors versus Tlx1 negative leukemias </plain></SENT>
</text></p><p id="P37"><text><SENT sid="164" pm="."><plain>Supplementary Table 3 Mouse Tlx1-signature genes ranking in the GSEA leading edge of human TLX1/TLX3 positive vs. TLX1/TLX3 negative T-ALLs. </plain></SENT>
</text></p><p id="P38"><text><SENT sid="165" pm="."><plain>Supplementary Table 4 Notch1 mutations in tumors from TLX1 transgenic mice. </plain></SENT>
</text></p><p id="P39"><text><SENT sid="166" pm="."><plain>Supplementary Table 5 Structural chromosomal alterations detected by aCGH in T- ALL from TLX1-transgenic mice. </plain></SENT>
</text></p><p id="P40"><text><SENT sid="167" pm="."><plain>Supplementary Table 6 Bcl11b mutations in mouse TLX1-induced T-ALLs. </plain></SENT>
</text></p><p id="P41"><text><SENT sid="168" pm="."><plain>Supplementary Table 7 BCL11B mutations and TLX1/TLX3 expression in human T- ALL. </plain></SENT>
</text></p><p id="P42"><text><SENT sid="169" pm="."><plain>Supplementary Table 8 Numerical chromosomal alterations identified in T-ALL tumors from TLX1 transgenic mice. </plain></SENT>
</text></p><p id="P43"><text><SENT sid="170" pm="."><plain>Supplementary Table 9 Differentially expressed genes in DN2 thymocytes isolated from TXL1-transgenic mice and normal littermate controls. </plain></SENT>
</text></p><p id="P44"><text><SENT sid="171" pm="."><plain>Supplementary Table 10 Promoters bound by TLX1 in TLX1 ChIP-chip experiments. </plain></SENT>
</text></p><p id="P45"><text><SENT sid="172" pm="."><plain>Supplementary Table 11 TLX1 ChIP-chip mitotic cell cycle (GO:0000278) direct targets (P &lt; 10−4) in the GSEA leading edge of DN2 thymocytes from wild type mice vs. DN2 cells from TLX1-transgenic mice. </plain></SENT>
</text></p><p id="P46"><text><SENT sid="173" pm="."><plain>Supplementary Table 12 Karyotype analysis of T-ALL samples from Total Therapy XII study. </plain></SENT>
</text></p><p id="P47"><text><SENT sid="174" pm="."><plain>Supplementary Table 13 Cytogenetic alterations associated with TLX1 and TLX3 tumors in 58881 and 58951 EORTC-Children Leukemia Group trials. </plain></SENT>
</text></p><p id="P48"><text><SENT sid="175" pm="."><plain>Supplementary Table 14 PCR and sequencing primers. </plain></SENT>
</text></p><p id="P49"><text><SENT sid="176" pm="."><plain>Supplementary Table 15 ChIP PCR and RT-PCR primers. </plain></SENT>
</text></p></caption><media xlink:href="NIHMS238550-supplement-1.pdf" mimetype="application" mime-subtype="pdf" xlink:type="simple" id="d37e1777" position="anchor"/></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack id="S24"><p><text4fund><text><SENT sid="177" pm="."><plain>This work was supported by a Blood Disease Research Project research grant from The New York Community Trust (A.F.); the National Institutes of Health (grants R01CA120196 and R01CA129382 to A.F.; NCA CA21765 to SR and U24 CA114737 to E.P.), the Spanish Ministry of Science and Innovation (fellowship EX-2006-0739 to P.J.R.), a Canceropole Ile-de-France Research research grant (J.S.), the Eeastern Cooperative Oncology Group (ECOG) tumor bank and the European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group, the Leukemia &amp; Lymphoma Society Scholar Award (A.F.) and the Intramural Program of the US National Institutes of Health (P.D.A.). </plain></SENT>
<SENT sid="178" pm="."><plain>K. </plain></SENT>
<SENT sid="179" pm="."><plain>D. </plain></SENT>
<SENT sid="180" pm="."><plain>K. is a postdoctoral researcher funded by the "Fonds voor Wetenschappelijk Onderzoek-Vlaanderen" and recipient of a Belgian American Educational Foundation (BAEF) fellowship. </plain></SENT>
<SENT sid="181" pm="."><plain>D.A. is recipient of a predoctoral fellowship from the France National Cancer Institute (INCa). </plain></SENT>
<SENT sid="182" pm="."><plain>We are also grateful to T. </plain></SENT>
<SENT sid="183" pm="."><plain>Ludwig for helpful discussions and S. </plain></SENT>
<SENT sid="184" pm="."><plain>Cory (Walter and Eliza Hall Institute of Medical Research) and H.G. </plain></SENT>
<SENT sid="185" pm="."><plain>Wendel (Memorial Sloan Kettering Cancer Center) for the VavP-Bcl2 mouse line </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><SecTag type="AUTH_CONT"><fn id="FN4" fn-type="con"><p><text><SENT sid="186" pm="."><plain>Author Contributions </plain></SENT>
</text></p><p><text><SENT sid="187" pm="."><plain>KDK performed cellular, genetic and molecular characterization of TLX1-induced tumors and preleukemic thymocytes, identified BCL11B mutations in mouse and human tumors and wrote the manuscript. </plain></SENT>
<SENT sid="188" pm="."><plain>PJR generated the TLX1 transgenic mice and characterized the tumor phenotype. </plain></SENT>
<SENT sid="189" pm="."><plain>GDG analyzed ChIP-chip data and gene expression signatures in human and mouse tumors. </plain></SENT>
<SENT sid="190" pm="."><plain>TP performed ChIP-chip. </plain></SENT>
<SENT sid="191" pm="."><plain>VT characterized mouse thymocytes. </plain></SENT>
<SENT sid="192" pm="."><plain>PVV and KDK analyzed array CGH data. </plain></SENT>
<SENT sid="193" pm="."><plain>MLS performed mouse tumor microarray analysis. </plain></SENT>
<SENT sid="194" pm="."><plain>KB and MH analyzed TLX1 transgenic lines. </plain></SENT>
<SENT sid="195" pm="."><plain>MC performed histological and immunohistochemical studies. </plain></SENT>
<SENT sid="196" pm="."><plain>JL, PA, MK, BK, PP, DK and FG provided mouse tumor samples. </plain></SENT>
<SENT sid="197" pm="."><plain>HP provided gene expression data on normal mouse thymocytes. </plain></SENT>
<SENT sid="198" pm="."><plain>XS analyzed ChIP-chip data. </plain></SENT>
<SENT sid="199" pm="."><plain>JVM and FS analyzed BCL11B mutations in human T-ALL samples. </plain></SENT>
<SENT sid="200" pm="."><plain>SR, HC, ND, JS and DA provided cytogenetic data on human T-ALLs. </plain></SENT>
<SENT sid="201" pm="."><plain>EP, JR, PW and JR provided human T-ALL specimens from ECOG clinical trials. </plain></SENT>
<SENT sid="202" pm="."><plain>JM generated human expression profiling data and characterized human T-ALL samples. </plain></SENT>
<SENT sid="203" pm="."><plain>CCC supervised histological and immunohistochemical studies. </plain></SENT>
<SENT sid="204" pm="."><plain>AC supervised the bioinformatic data analysis. </plain></SENT>
<SENT sid="205" pm="."><plain>AAF designed the study, supervised research and wrote the manuscript. </plain></SENT>
</text></p></fn></SecTag><fn id="FN5"><p><text><SENT sid="206" pm="."><plain>Accession codes </plain></SENT>
</text></p><p><text><SENT sid="207" pm="."><plain>Microarray data are available at Gene Expression Omnibus (accession numbers GSE19499 and GSE10609). </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><ref id="R1"><text><SENT sid="208" pm="."><plain>1FerrandoAAPrognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemiaLancet363535536200414975618 </plain></SENT>
</text></ref><ref id="R2"><text><SENT sid="209" pm="."><plain>2FerrandoAAGene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemiaCancer Cell17587200212086890 </plain></SENT>
</text></ref><ref id="R3"><text><SENT sid="210" pm="."><plain>3KeesURExpression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG)Leukemia17887893200312750702 </plain></SENT>
</text></ref><ref id="R4"><text><SENT sid="211" pm="."><plain>4BergerRt(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. </plain></SENT>
<SENT sid="212" pm="."><plain>A collaborative study of the Groupe Francais de Cytogenetique Hematologique (GFCH)Leukemia1718511857200312970786 </plain></SENT>
</text></ref><ref id="R5"><text><SENT sid="213" pm="."><plain>5BernardOAA new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemiaLeukemia15 14951504200111587205 </plain></SENT>
</text></ref><ref id="R6"><text><SENT sid="214" pm="."><plain>6BergeronJPrognostic and oncogenic relevance of TLX1/HOX11 expression level in TALLsBlood11023242330200717609427 </plain></SENT>
</text></ref><ref id="R7"><text><SENT sid="215" pm="."><plain>7GrauxCFusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemiaNat Genet3610841089200415361874 </plain></SENT>
</text></ref><ref id="R8"><text><SENT sid="216" pm="."><plain>8ToselloVWT1 mutations in T-ALLBlood11410381045200919494353 </plain></SENT>
</text></ref><ref id="R9"><text><SENT sid="217" pm="."><plain>9Van VlierberghePPHF6 mutations in T-cell acute lymphoblastic leukemiaNat Genet2010 </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="218" pm="."><plain>10ChaffinKEDissection of thymocyte signaling pathways by in vivo expression of pertussis toxin ADP-ribosyltransferaseEMBO J93821382919902123451 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="219" pm="."><plain>11WildinRSDevelopmental regulation of lck gene expression in T lymphocytesJ Exp Med17338339319911988541 </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="220" pm="."><plain>12GouldJGetzGMontiSReichMMesirovJPComparative gene marker selection suiteBioinformatics2219241925200616709585 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="221" pm="."><plain>13WengAPActivating mutations of NOTCH1 in human T cell acute lymphoblastic leukemiaScience306269271200415472075 </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="222" pm="."><plain>14SulisMLNOTCH1 extracellular juxtamembrane expansion mutations in T-ALLBlood112733740200818411416 </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="223" pm="."><plain>15PalomeroTMutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemiaNat Med1312031210200717873882 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="224" pm="."><plain>16MaserRSChromosomally unstable mouse tumours have genomic alterations similar to diverse human cancersNature447966971200717515920 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="225" pm="."><plain>17KawamuraMAlterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemiaLeuk Res23115126199910071127 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="226" pm="."><plain>18MullighanCGGenome-wide analysis of genetic alterations in acute lymphoblastic leukaemiaNature446758764200717344859 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="227" pm="."><plain>19WakabayashiYBcl11b is required for differentiation and survival of alphabeta T lymphocytesNat Immunol4533539200312717433 </plain></SENT>
</text></ref><ref id="R20"><text><SENT sid="228" pm="."><plain>20AlbuDIBCL11B is required for positive selection and survival of double-positive thymocytesJ Exp Med20430033015200717998389 </plain></SENT>
</text></ref><ref id="R21"><text><SENT sid="229" pm="."><plain>21HatanoMRobertsCWMindenMCristWMKorsmeyerSJDeregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemiaScience253798219911676542 </plain></SENT>
</text></ref><ref id="R22"><text><SENT sid="230" pm="."><plain>22KawabeTMuslinAJKorsmeyerSJHOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpointNature38545445819979009195 </plain></SENT>
</text></ref><ref id="R23"><text><SENT sid="231" pm="."><plain>23ChenEDysregulated expression of mitotic regulators is associated with B-cell lymphomagenesis in HOX11-transgenic miceOncogene2525752587200616407851 </plain></SENT>
</text></ref><ref id="R24"><text><SENT sid="232" pm="."><plain>24ChandhokNSPellmanDA little CIN may cost a lot: revisiting aneuploidy and cancerCurr Opin Genet Dev197481200919195877 </plain></SENT>
</text></ref><ref id="R25"><text><SENT sid="233" pm="."><plain>25MargolinAAChIP-on-chip significance analysis reveals large-scale binding and regulation by human transcription factor oncogenesProc Natl Acad Sci U S A106244249200919118200 </plain></SENT>
</text></ref><ref id="R26"><text><SENT sid="234" pm="."><plain>26HebertJCayuelaJMBerkeleyJSigauxFCandidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemiasBlood844038404419947994022 </plain></SENT>
</text></ref><ref id="R27"><text><SENT sid="235" pm="."><plain>27KamimuraKHaploinsufficiency of Bcl11b for suppression of lymphomagenesis and thymocyte developmentBiochem Biophys Res Commun355538542200717306224 </plain></SENT>
</text></ref><ref id="R28"><text><SENT sid="236" pm="."><plain>28OgilvySConstitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survivalProc Natl Acad Sci U S A961494314948199910611317 </plain></SENT>
</text></ref><ref id="R29"><text><SENT sid="237" pm="."><plain>29EgleAHarrisAWBathMLO'ReillyLCorySVavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasiaBlood10322762283200414630790 </plain></SENT>
</text></ref><ref id="R30"><text><SENT sid="238" pm="."><plain>30LiCWongWHModel-based analysis of oligonucleotide arrays: expression index computation and outlier detectionProc Natl Acad Sci U S A983136200111134512 </plain></SENT>
</text></ref><ref id="R31"><text><SENT sid="239" pm="."><plain>31ReichMGenePattern 2.0Nat Genet38500501200616642009 </plain></SENT>
</text></ref><ref id="R32"><text><SENT sid="240" pm="."><plain>32Van VlierberghePThe recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemiaBlood11146684680200818299449 </plain></SENT>
</text></ref><ref id="R33"><text><SENT sid="241" pm="."><plain>33VilimasTTargeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemiaNat Med137077200717173050 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="F1" position="float"><label>Fig. 1</label><caption><p><text><SENT sid="242" pm="."><plain>TLX1-induced T-cell leukemias in mice. </plain></SENT>
<SENT sid="243" pm="."><plain>(a) Kaplan-Meier survival curves of p56Lck-TLX1 transgenic mice and littermate controls from three independent founder lines. </plain></SENT>
<SENT sid="244" pm="."><plain>Accelerated mortality in TLX1 transgenic mice was associated with the development of immature T-cell tumors. </plain></SENT>
<SENT sid="245" pm="."><plain>(b) Infiltration of thymus, spleen, bone marrow and liver by immature lymphoblasts. </plain></SENT>
<SENT sid="246" pm="."><plain>(c) Western blot analysis of TLX1 expression in mouse T-cell tumors. </plain></SENT>
<SENT sid="247" pm="."><plain>(d-e) Immunohistochemical analysis of TLX1 (d) and CD3 expression in mouse TLX1-induced T-ALL cells (e). </plain></SENT>
<SENT sid="248" pm="."><plain>Scale bar 100 μm. </plain></SENT>
<SENT sid="249" pm="."><plain>(f,g) Immunophenotype distribution (f) and representative flow cytometry plots (g) showing heterogeneous expression of CD4 and CD8 in TLX1-induced leukemias. </plain></SENT>
<SENT sid="250" pm="."><plain>DN, double negative; DP, double positive; SP, single positive. </plain></SENT>
<SENT sid="251" pm="."><plain>(h) Clonality analysis by expression of TCRB chains in TLX1-induced tumors. </plain></SENT>
<SENT sid="252" pm="."><plain>Polyclonal expression of TCRB in normal thymocytes is shown as control (upper row). </plain></SENT>
</text></p></caption><graphic xlink:href="nihms238550f1"/></fig></SecTag><SecTag type="FIG"><fig id="F2" position="float"><label>Fig. 2</label><caption><p><text><SENT sid="253" pm="."><plain>Molecular signatures associated with TLX1-induced transformation. </plain></SENT>
<SENT sid="254" pm="."><plain>(a) Heat map diagram of the 50 top ranking differentially expressed genes by t-test in mouse TLX1-induced leukemias. </plain></SENT>
<SENT sid="255" pm="."><plain>(b) GSEA analysis of differentially expressed genes associated with TLX1-induced transformation in mice demonstrates enrichment of this signature in human TLX1/TLX3 expressing T-ALLs. </plain></SENT>
<SENT sid="256" pm="."><plain>Gene set: Human orthologs of mouse TLX1 signature genes. </plain></SENT>
<SENT sid="257" pm="."><plain>Data set: TLX1/TLX3 positive vs. TLX1/TLX3 negative human leukemias. </plain></SENT>
<SENT sid="258" pm="."><plain>Enrichment plots (left) and heat map representations of the 50 top ranking genes in the leading edge (right) are shown. </plain></SENT>
<SENT sid="259" pm="."><plain>Genes in heat maps are shown in rows, each individual sample is shown in one column. </plain></SENT>
<SENT sid="260" pm="."><plain>The scale bar shows color coded differential expression from the mean in standard deviation units with red indicating higher levels and blue lower levels of expression. </plain></SENT>
</text></p></caption><graphic xlink:href="nihms238550f2"/></fig></SecTag><SecTag type="FIG"><fig id="F3" position="float"><label>Fig 3</label><caption><title>Developmental defects in thymocyte development in <italic>TLX1</italic>-transgenic mice</title><p><text><SENT sid="261" pm="."><plain>(a) Preleukemic TLX1 transgenic mice at 6 weeks of age showed decreased thymus weight and cellularity compared with littermate controls. </plain></SENT>
<SENT sid="262" pm="."><plain>Scale bar 10 mm. </plain></SENT>
<SENT sid="263" pm="."><plain>(b) Cell cycle analysis of control and preleukemic TLX1-transgenic thymocytes via PI staining of DNA content analyzed by flow cytometry. </plain></SENT>
<SENT sid="264" pm="."><plain>(c) Flow cytometry analysis of T-cell development in preleukemic TLX1-transgenic animals. </plain></SENT>
<SENT sid="265" pm="."><plain>Accumulation of CD44+CD25+ cells shows a differentiation block at the DN2 stage of thymocyte development. </plain></SENT>
<SENT sid="266" pm="."><plain>(d) Apoptosis analysis of control and TLX1-transgenic preleukemic thymocytes via annexinV/PI staining. </plain></SENT>
<SENT sid="267" pm="."><plain>(e) TUNEL staining on thymus tissue sections. </plain></SENT>
<SENT sid="268" pm="."><plain>Scale bars represent 100 μm. </plain></SENT>
<SENT sid="269" pm="."><plain>(f-h) Transgenic expression of BCL2 inhibits apoptosis (f) and reverses thymic weight (g) and cellularity (h) in preleukemic TLX1 +BCL2 double transgenic mice. </plain></SENT>
</text></p></caption><graphic xlink:href="nihms238550f3"/></fig></SecTag><SecTag type="FIG"><fig id="F4" position="float"><label>Fig. 4</label><caption><p><text><SENT sid="270" pm="."><plain>Numerical and structural chromosomal alterations in TLX1-induced mouse T-ALLs. </plain></SENT>
<SENT sid="271" pm="."><plain>(a) Mouse chromosomal ideogram showing the areas of genetic gain and loss identified by aCGH in TLX1 thymic tumors. </plain></SENT>
<SENT sid="272" pm="."><plain>Red bars represent areas of gain. </plain></SENT>
<SENT sid="273" pm="."><plain>Green bars represent areas of copy number loss. </plain></SENT>
<SENT sid="274" pm="."><plain>(b) Schematic representation of the chromosome 12q commonly deleted region encompassing the Bcl11b locus in mouse TLX1-induced tumors. </plain></SENT>
<SENT sid="275" pm="."><plain>(c) Array CGH plot showing a focal deletion of the Bcl11b gene in a mouse TLX1-induced T-ALL. </plain></SENT>
<SENT sid="276" pm="."><plain>(d) Schematic representation of Bcl11b mutations identified in mouse TLX1-induced T-ALLs. </plain></SENT>
<SENT sid="277" pm="."><plain>(e) DNA sequence chromatograms corresponding to Bcl11b mutations identified in mouse TLX1-induced T-ALLs. </plain></SENT>
</text></p></caption><graphic xlink:href="nihms238550f4"/></fig></SecTag><SecTag type="FIG"><fig id="F5" position="float"><label>Fig. 5</label><caption><p><text><SENT sid="278" pm="."><plain>BCL11B is a TLX1 target gene mutated in human T-ALL. </plain></SENT>
<SENT sid="279" pm="."><plain>(a) Array CGH plots showing focal deletions in chromosomal band 14q32.2 encompassing the BCL11B locus in human T-ALL. </plain></SENT>
<SENT sid="280" pm="."><plain>(b) Schematic representation of BCL11B mutations identified in human T-ALL. </plain></SENT>
<SENT sid="281" pm="."><plain>(c) DNA sequence analysis of BCL11B in diagnostic and remission T-ALL samples. </plain></SENT>
<SENT sid="282" pm="."><plain>(d) ChIP analysis of TLX1 binding to BCL11B regulatory sequences in ALL-SIL cells. </plain></SENT>
<SENT sid="283" pm="."><plain>(e) Western blot analysis of TLX1 and RT-PCR analysis of BCL11B expression in ALL-SIL cells electroporated with control or TLX1 siRNAs. </plain></SENT>
</text></p></caption><graphic xlink:href="nihms238550f5"/></fig></SecTag><SecTag type="FIG"><fig id="F6" position="float"><label>Fig. 6</label><caption><p><text><SENT sid="284" pm="."><plain>Numerical chromosomal alterations and defects in the mitotic checkpoint in TLX-transgenic mice. </plain></SENT>
<SENT sid="285" pm="."><plain>(a) SKY analysis of a mouse TLX1-induced tumor with trisomy 15. </plain></SENT>
<SENT sid="286" pm="."><plain>(b) Distribution of numerical chromosomal aberrations found by SKY and aCGH analysis in mouse TLX1-induced leukemias. </plain></SENT>
<SENT sid="287" pm="."><plain>(c) Cell cycle analysis of vehicle only, taxol and nocodazole treated mouse T-ALLs showing defective activation of the mitotic checkpoint in mouse TLX1-positive leukemia cells. </plain></SENT>
<SENT sid="288" pm="."><plain>(d) GSEA analysis of mitotic regulators identified as TLX1 direct target genes by ChIP-chip in sorted thymocytes (DN2 cells) from wild type and preleukemic TLX1 transgenic mice. </plain></SENT>
<SENT sid="289" pm="."><plain>Gene set: TLX1 direct targets in mitotic cell cycle (GO:0000278). </plain></SENT>
<SENT sid="290" pm="."><plain>Data set: TLX1 transgenic preleukemic cells vs. wild type. </plain></SENT>
<SENT sid="291" pm="."><plain>The enrichment plot (left) and heat map representation of the top 25 mitotic genes in the rank of transcripts differentially expressed in TLX1-preleukemic cells (right) are shown. </plain></SENT>
<SENT sid="292" pm="."><plain>The scale bar at the bottom shows color coded differential expression from the mean in standard deviation units with red indicating higher levels and blue lower levels of expression. </plain></SENT>
<SENT sid="293" pm="."><plain>(e) RT-PCR analysis of Chek1 expression in thymocytes isolated from wild type or TLX1-transgenic mice. </plain></SENT>
<SENT sid="294" pm="."><plain>(f) ChIP analysis of TLX1 binding to CHEK1 regulatory sequences in ALL-SIL cells. </plain></SENT>
<SENT sid="295" pm="."><plain>(g) RT-PCR analysis of TLX1 and CHEK1 expression in ALL-SIL cells electroporated with control or TLX1 siRNAs. </plain></SENT>
<SENT sid="296" pm="."><plain>(h) Cell cycle analysis of vehicle only and taxol treated mouse thymocytes from BCL2 transgenic and TLX1-BCL2 double transgenic mice showing defective activation of the mitotic checkpoint in mouse TLX1-BCL2-expressing preleukemic cells. </plain></SENT>
</text></p></caption><graphic xlink:href="nihms238550f6"/></fig></SecTag></floats-group></article>
